Data for "Hypergammaglobulinemia in treated and untreated people with HIV"

This dataset contains pseudo-anonymized information on sex, age and blood samples (n = 821), of which 750 samples are from 584 adult (age ≥ 18 years) persons with HIV (PWH) and 71 from HIV-negative controls. The blood samples from the PWH were collected in a standardized manner during outpatient clinic visits as part of "the Gothenburg HIV CSF Study Cohort" at the Department of Infectious Diseases, at the Sahlgrenska University Hospital, Gothenburg, Sweden. Data became available at the time of sample collection and were compiled for analysis between 13/11/1985 and 14/03/2023. The samples from the HIV-positive participants were categorized according to eight categories representing immunologically different stages of HIV infection: primary HIV infection (PHI; within 12 months of initial HIV infection), five groups characterized by CD4+ T cell counts (≥ 500; 350−499; 200−349, 50−199 and < 50 cells/μL), ongoing infection or malignancy (OIM), and those on ART. The diagnosis of PHI was based on a combination of clinical histories and seroconversion, nucleic acid testing or enzyme-linked immunosorbent assay (ELISA) testing. OIM was defined as the presence of an opportunistic or non-opportunistic bacterial, viral or parasitic infection or active cancer in association with or within two weeks of blood sampling. ART suppression was defined as ongoing ART with plasma HIV-RNA < 50 copies/mL for ≥ 6 months and included antiretroviral regimens with two or more active agents (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors and/or protease inhibitors) according to guidelines existing at the time of inclusion. The HIV-negative control group (n = 71) consisted of 44 individuals receiving HIV preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) and 27 volunteers (healthcare workers, students and their relatives) without PrEP. The blood samples were analyzed for IgG, neopterin, β2-microglobulin, albumin, HIV-RNA, CD4+, and CD4+ nadir. Additionally, information on antiretroviral therapy, the duration of viral suppression as well as hepatitis C status are provided. Data on hepatitis C status were extracted from the Swedish InfCareHIV cohort.